Russian COVID-19 vaccine trial data published


  • Dawn O'Shea
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Data from the trial of the Russian COVID-19 vaccine, Sputnik V, have been published in the Lancet.

The paper reports the findings of two open non-randomised phase 1/2 trials of a heterologous COVID-19 vaccine consisting of recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector, carrying the gene for SARS-CoV-2 spike glycoprotein (rAd26-S and rAd5-S).

The trials enrolled 76 healthy adult volunteers. In phase 1 of each study, participants received one dose of rAd26-S or rAd5-S on day 0. Safety was assessed at 28 days. In phase 2, participants received a prime-boost vaccination.

The most common adverse events were injection site pain (58%), hyperthermia (50%), headache (42%), asthenia (28%), and muscle and joint pain (24%). No serious adverse events were detected, the authors report.

All participants produced antibodies to SARS-CoV-2 glycoprotein. At day 42, receptor binding domain-specific IgG titres were 14,703 with the frozen formulation and 11,143 with the lyophilised formulation. Neutralising antibodies were 49.25 and 45.95, respectively. Seroconversion rate was 100 per cent.

Cell-mediated responses were detected in all participants at day 28. Median cell proliferation was 2.5 per cent CD4+ and 1.3 per cent CD8+ with the frozen formulation, and 1.3 and 1.1 per cent with the lyophilised formulation.